Dealing With MedImmune

Law360, New York (March 13, 2007, 12:00 AM EDT) -- In MedImmune v. Genentech, 127 S. Ct. 764 (2007), the Supreme Court held that a patent licensee does not have to repudiate the license in order to file a declaratory judgment action challenging the validity of the underlying patent.

Many observers believe that this decision will fundamentally alter the negotiating positions of prospective licensors and licensees. Until MedImmune, a licensee could not make a validity challenge without first repudiating the license, refusing to pay royalties and infringing the patent.

The licensee would then face major risks...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.